It’s a public unlisted company and is classified as’company limited by shares
Intas Pharma Ltd. (Amalgamated) was incorporated in 2000 In the latest quarter, the company reported Gross Sales of ₹697.55 Cr and Total Income of ₹730.64 Cr, with a management team including Drigesh Pramod Mittal, Nimish Hasmukh Bhai Chudgar, Hasmukh Chudgar, Binish Hasmukh Chudgar, and Urmish Hasmukh Chudgar.
| Details | Information |
|---|---|
| CIN | U24231GJ1985PLC007866 |
| Date of Incorporation | 31 May, 1985 |
| Status | Active |
| Company Category | Company limited by Shares |
| Company Sub-category | Non-govt company |
| Company Class | Public |
| Business Activity | Manufacturing (Metals & Chemicals, and products thereof) |
| Authorized Capital | 17391.67 lakhs |
| Paid-up Capital | 11474.4 lakhs |
| Paid-up Capital % | 65.97638 |
| Registrar Office City | Ahmedabad |
| Registered State | Gujarat |
| Registration Number | 7866 |
| Registration Date | 31 May, 1985 |
| Listing Status | Unlisted |
| AGM last held on | 29 Sep, 2017 |
| Balance Sheet last updated | 31 Mar, 2017 |
| Additional Data | |
| Business Focus | Manufacturing metals, chemicals, and related products |
| Authorized Capital | 17391.67 lakhs |
| Paid-up Capital | 11474.4 lakhs |
| Paid-up Capital % | 65.97638 |
| Last AGM Date | 29 Sep, 2017 |
| Last Balance Sheet Date | 31 Mar, 2017 |
Intas Pharmaceuticals, a leading pharmaceutical company, has seen fluctuations in its share price over time, influenced by various factors. Here is an analysis of the key factors affecting Intas Pharma’s share price in May 2024:
Positive Factors:
- Financial Performance: Very Strong Financial Result and revenue growth
- Regulatory Approvals and Product Pipeline: Intas has got regulatory approvals for new drug launches new product pipelines
- Market Expansion and Diversification: Intas Pharmaceuticals has been expanding globally
Negative Factors:
- Market Competition and Industry Trends: Pharma Industry is Extremely Sensitive
- Global Economic Conditions: Macroeconomic factors like high interest rate fluctuations and negative market sentiments
- Negative COVID-19 Pandemic: Intas Pharmaceuticals’ operations, financial performance, and share price was impacted due to COVID-19
